Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Resistance mutations in BTK and PLCG2 are common in patients with CLL who progress on acalabrutinib, a BTK inhibitor treatment that is taken continuously.
An interim analysis of the AMPLIFY trial comparing acalabrutinib and venetoclax with or without obinutuzumab for CLL shows improvements in patient survival.
A Matching-Adjusted Indirect Comparison (MAIC) Case Study: Zanubrutinib vs. Acalabrutinib Education Activity
Acalabrutinib may be taken alone or in combination with obinutuzumab as a preferred initial (first-line) treatment, or alone as a second- or thirdline treatment.
Zanubrutinib is an excellent option for patients with CLL / SLL who are unable to tolerate acalabrutinib due to side effects.
Acalabrutinib has a low risk of sudden death and ventricular arrhythmias in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) patients.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL) patients do better when their first therapy is acalabrutinib based compared to chemoimmunotherapy.
Acalabrutinib and zanubrutinib have similar excellent efficacy in relapsed or refractory chronic lymphocytic leukemia (CLL).
One click to our most popular content.
